$15.08
0.33% yesterday
NYSE, Jun 02, 10:10 pm CET
ISIN
US8740602052
Symbol
TAK
Sector
Industry

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Target price 2025 - Analyst rating & recommendation

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Classifications & Recommendation:

Buy
53%
Hold
47%

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Price Target

Target Price $17.20
Price $15.08
Potential
Number of Estimates 13
13 Analysts have issued a price target Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2026 . The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR target price is $17.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 8 Analysts recommend Takeda Pharmaceutical Co. Ltd. Sponsored ADR to buy, 7 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock has an average upside potential 2026 of . Most analysts recommend the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion $ 32.12 31.53
7.45% 1.81%
EBITDA Margin 21.52% 29.27%
3.66% 36.03%
Net Margin 2.36% 2.71%
30.28% 15.04%

12 Analysts have issued a sales forecast Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2026 . The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR sales estimate is

$31.5b
Unlock
. This is
1.81% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$32.3b 0.58%
Unlock
, the lowest is
$29.6b 7.91%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $32.1b 7.45%
2026
$31.5b 1.81%
Unlock
2027
$31.9b 1.11%
Unlock
2028
$32.7b 2.56%
Unlock
2029
$33.8b 3.44%
Unlock
2030
$34.2b 1.01%
Unlock

9 Analysts have issued an Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA forecast 2026. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA estimate is

$9.2b
Unlock
. This is
37.55% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$14.2b 112.30%
Unlock
, the lowest is
$7.3b 8.69%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $6.9b 3.52%
2026
$9.2b 33.58%
Unlock
2027
$9.4b 2.34%
Unlock
2028
$10.1b 6.88%
Unlock
2029
$10.1b 0.23%
Unlock
2030
$7.9b 21.33%
Unlock

EBITDA Margin

2025 21.52% 3.66%
2026
29.27% 36.03%
Unlock
2027
29.63% 1.23%
Unlock
2028
30.88% 4.22%
Unlock
2029
29.78% 3.56%
Unlock
2030
23.19% 22.13%
Unlock

8 Takeda Pharmaceutical Co. Ltd. Sponsored ADR Analysts have issued a net profit forecast 2026. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR net profit estimate is

$854m
Unlock
. This is
12.94% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.1b 47.49%
Unlock
, the lowest is
$430m 43.16%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $757m 25.08%
2026
$854m 12.94%
Unlock
2027
$1.0b 19.31%
Unlock
2028
$1.1b 9.83%
Unlock
2029
$1.5b 31.74%
Unlock

Net Margin

2025 2.36% 30.28%
2026
2.71% 15.04%
Unlock
2027
3.20% 18.08%
Unlock
2028
3.42% 6.88%
Unlock
2029
4.36% 27.49%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Mar '25 2026
Estimates
Earnings Per Share $ 0.48 0.54
26.15% 12.50%
P/E 27.77
EV/Sales 2.43

8 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast for earnings per share. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR EPS is

$0.54
Unlock
. This is
12.50% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$0.71 47.92%
Unlock
, the lowest is
$0.27 43.75%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $0.48 26.15%
2026
$0.54 12.50%
Unlock
2027
$0.65 20.37%
Unlock
2028
$0.71 9.23%
Unlock
2029
$0.94 32.39%
Unlock

P/E ratio

Current 31.42 50.61%
2026
27.77 11.61%
Unlock
2027
23.28 16.17%
Unlock
2028
21.19 8.98%
Unlock
2029
16.09 24.07%
Unlock

Based on analysts' sales estimates for 2026, the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.39 1.65%
2026
2.43 1.82%
Unlock
2027
2.41 1.10%
Unlock
2028
2.35 2.49%
Unlock
2029
2.27 3.32%
Unlock
2030
2.25 1.00%
Unlock

P/S ratio

Current 1.49 6.24%
2026
1.52 1.84%
Unlock
2027
1.50 1.09%
Unlock
2028
1.47 2.49%
Unlock
2029
1.42 3.32%
Unlock
2030
1.40 1.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today